Tr1X Bio

Changing the game — aiming to cure

United States · Founded 2018 · $75.0M raised

Employees
11–50
Founded
2018
Business Model
B2B
Website
tr1x.bio
Total Funding
$75.0M
Last Round
$75.0M Series AJan 2024
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Tr1X develops a novel class of regulatory T cell-based therapies to treat and ultimately cure autoimmune and inflammatory diseases with high unmet medical need. The company translates academic findings in Type 1 regulatory T cell biology into scalable immunotherapies designed to restore immune tolerance. Its mission is to shift the field from chronic treatment toward cures and to become a global leader in Tr1-based medicines. Headquartered in San Diego, Tr1X is advancing off-the-shelf allogeneic cell therapy programs from bench to bedside for patients worldwide.

Summary

Tr1X Bio is a Biotech company based in United States, founded in 2018. It has raised $75.0M in total across 1 round, most recently a $75.0M Series A round in Jan 2024.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJan 2024
$75.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Tr1X Bio on Indexed.vc
<a href="https://indexed.vc/companies/tr1x-bio"><img src="https://indexed.vc/api/badge/company/tr1x-bio" alt="Tr1X Bio on Indexed.vc" width="260" height="76" /></a>